HLS Therapeutics, Inc.

As of June 30, 2026, HLS Therapeutics, Inc. carries a market capitalization of 141.37M, placing it among publicly traded companies globally. Its enterprise value stands at 181.35M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

HLS Therapeutics, Inc.'s next confirmed earnings release is scheduled for November 5, 2026.

As of June 30, 2026, HLS Therapeutics, Inc. has 31.27M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 1.84, and the price-to-book ratio stands at 1.80.

As of June 30, 2026, HLS Therapeutics, Inc. trades at an EV/EBITDA multiple of 7.95 - the valuation measure that neutralizes differences in capital structure, tax rates, and depreciation policy, making it the standard yardstick for comparing companies across an industry. The EV/Sales ratio of 2.27 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 181.35M versus a market cap of 141.37M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, HLS Therapeutics, Inc. maintains a current ratio of 1.05, meaning it holds 1.1x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 75.86, indicating elevated leverage, while an interest coverage ratio of 3.29 demonstrates adequate ability to service its debt obligations.

Over the twelve months ended June 30, 2026, HLS Therapeutics, Inc. posted a negative return on equity (ROE) of -14.07, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -6.17, reflecting losses generated across the asset base. The company generates approximately 920,122.51 in revenue per employee across its workforce of 86.75, a quick read on workforce productivity versus industry peers. Inventory turnover of 1.65 indicates how many times HLS Therapeutics, Inc. sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, HLS Therapeutics, Inc. recorded an income tax benefit of -921,067.29 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -13.08M and -12.16M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 16, 2026, HLS Therapeutics, Inc.'s stock has declined approximately 24.27% over the past 52 weeks. The 50-day moving average sits at 4.48, while the 200-day moving average is 5.20.

Over the twelve months ended June 30, 2026, HLS Therapeutics, Inc. generated 79.82M in revenue and converted that into -12.16M in net income, yielding earnings per share of -0.37. EBITDA reached 22.82M, while operating income came in at -6.40M.

As of June 30, 2026, HLS Therapeutics, Inc. holds 19.49M in cash and equivalents against 59.47M in total debt, resulting in a net debt position of 38.96M. Total book value stands at 78.39M, with working capital of 2.02M providing operational flexibility.

HLS Therapeutics, Inc. produced 25.90M in operating cash flow over the twelve months ended June 30, 2026. After subtracting -1.47M in capital expenditures, free cash flow totaled 24.43M - equivalent to 0.75 per share.

Over the twelve months ended June 30, 2026, HLS Therapeutics, Inc. posted a gross margin of 80.95, reflecting its pricing power and cost economics. The operating margin of -8.02 and net profit margin of -15.24 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2026. Free cash flow yield stands at 16.62, showing how much cash the business generates relative to its market value - dividends covered by free cash flow are generally more durable than those funded by debt. Total shareholder yield reaches 15.36, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to HLS Therapeutics, Inc. shareholders.

As of June 30, 2026, HLS Therapeutics, Inc. has an Altman Z-Score of -6.65, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.